Compare GSK plc (GSK) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs United Airlines Holdings Inc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while United Airlines Holdings Inc trades at $107.46 (market cap $34.87B). The key difference: GSK plc is far larger — about 2.6× United Airlines Holdings Inc's market cap, and GSK plc pays a 3.9% dividend while United Airlines Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and United Airlines Holdings Inc for 46 Days on average.
| GSK | UAL | |
|---|---|---|
Market Cap | $91.88B | $34.87B |
Volume | 7,730,529 | 6,329,678 |
Sector | Health | Industrials |
52-Week High | $61.18 | $136.11 |
52-Week Low | $43.24 | $85.21 |
Typical Hold Time | 93 Days | 46 Days |
Enterprise Value | $111.88B | $51.90B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
United Airlines (UAL) trades at $107.44, down 2.48% on the day, reflecting near-term pressure amid a bearish technical signal. Fundamentally, the company shows strength with a low P/E of 10.06, robust ROE of 23.25%, and consistent earnings beats in recent quarters. Recent news highlights aggressive customer acquisition efforts targeting Delta and American Airlines' premium flyers, leveraging Starlink WiFi partnerships to enhance its competitive edge.
The outlook is mixed: strong analyst consensus (66% buy ratings) and a $158.10 price target suggest upside, but rising fuel costs and bearish technicals pose near-term risks. Earnings sustainability and market share gains from strategic moves are key catalysts, while volatility in travel demand remains a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
